Regulatory agency issues guidance on identifying counterfeit and unauthorized medications

The agency has released protocols for distinguishing between legitimate, counterfeit, and experimental pharmaceutical products. This advisory follows concerns regarding the health risks associated with unauthorized imported medications, though it does not specify a particular surge in illicit activity.